SVB Leerink Maintains Outperform on Bio-Techne, Lowers Price Target to $500
SVB Leerink analyst Puneet Souda maintains Bio-Techne (NASDAQ:TECH) with a Outperform and lowers the price target from $550 to $500.
Credit Suisse Initiates Coverage On Bio-Techne with Outperform Rating, Announces Price Target of $465
Credit Suisse analyst Dan Leonard initiates coverage on Bio-Techne (NASDAQ:TECH) with a Outperform rating and announces Price Target of $465.
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Wells Fargo Maintains Underweight on Bio-Techne, Lowers Price Target to $360
Wells Fargo analyst Timothy Daley maintains Bio-Techne (NASDAQ:TECH) with a Underweight and lowers the price target from $370 to $360.
Bio-Techne Announces CEO Transition Plan
Bio-Teche Corporation (NASDAQ:TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024. The
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.